Simvastatin is a potential candidate drug in ovarian clear cell carcinomas

Ovarian clear cell carcinomas (OCCC) constitute a rare subtype of epithelial ovarian cancer, lacking efficient treatment options. Based on previous studies, we assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G,...

Descripción completa

Detalles Bibliográficos
Autores principales: Arildsen, Nicolai Skovbjerg, Hedenfalk, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546754/
https://www.ncbi.nlm.nih.gov/pubmed/33088426
http://dx.doi.org/10.18632/oncotarget.27747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546754/
https://www.ncbi.nlm.nih.gov/pubmed/33088426
http://dx.doi.org/10.18632/oncotarget.27747

Ejemplares similares